[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100330126":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":13,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":32,"responsibleParty":81,"collaborators":13,"id":85,"slug":13,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":13,"enrollmentInfo":93,"targetDuration":13,"studyType":96,"phases":13,"briefSummary":97,"conditions":98,"keywords":13,"overallStatus":34,"whyStopped":13,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"List of biomarkers","Neoantigen, tumor mutation burden, MHC compatibility, T-cell receptor and associated immune gene signature (IFN-r, interferons such as IL-2 and interleukin family), T-cell subset (T cell surface marker such as CD4+, CD7+, CD8+, CD16, CD34+, CD38+, CD56+, etc.), PD-1\u002FPD-L1 expression, etc.","Baseline",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","RETROSPECTIVE","\\[Sample acquisition\\]\n\n* Informed consent is waived for those who agree to donate samples left over from other clinical trials or acquired for other purposes to be used for other research by the sign to master agreement in advance.\n* The study will be conducted based on the purposes indicated in the master agreement signed by tissue donator \\[Clinical data acquisition\\]\n* Baseline demographics: Sex, Birth date, expire date (last follow-up date for the survivals)\n* Lung cancer treatment history: diagnosed date, treatment history (surgery, radiation therapy, chemotherapy, immunotherapy treatment history, and responses), general performance, metastatic sites\n* Lung cancer histologic information: pathology, histologic subtype, EGFR mutation profile, ALK-rearrangement result","Total of 800 lung cancer patients treated with immune checkpoint inhibitor Study will be initiated from the date of IRB approval to Dec. 2020 for those who signed for master agreement for tissue donation for research purposes.",[20],{"name":21,"affiliation":5,"role":22},"Se-hoon Lee, MD","STUDY_CHAIR",[24,28],{"name":21,"role":25,"phone":26,"phoneExt":13,"email":27},"CONTACT","+82-10-4759-7640","sehoon.lee@samsung.com",{"name":29,"role":25,"phone":30,"phoneExt":13,"email":31},"Jinhee Seo","+82-70-7014-4158","rufina.seo@samsung.com",[33,51,65],{"facility":5,"status":34,"city":35,"state":36,"zip":13,"country":37,"countryCode":13,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Seoul","Gangnam-gu","South Korea",{"type":39,"coordinates":40},"Point",[41,42],126.9784,37.566,{"lat":42,"lon":41},[45,49],{"name":21,"role":25,"phone":46,"phoneExt":47,"email":48},"70-7014-4158","82","sehoon.lee119@gmail.com",{"name":50,"role":25,"phone":46,"phoneExt":47,"email":31},"Jinhee Seo, RN",{"facility":52,"status":34,"city":35,"state":53,"zip":13,"country":37,"countryCode":13,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"Seoul National University Hospital","Joungro-gu",{"type":39,"coordinates":55},[41,42],{"lat":42,"lon":41},[58,62],{"name":59,"role":25,"phone":60,"phoneExt":47,"email":61},"Tae-min Kim, MD","2-2072-3559","gabriel9@snu.ac.kr",{"name":63,"role":25,"phone":13,"phoneExt":13,"email":64},"So-yun Kim, MD","thdus81@hanmail.net",{"facility":66,"status":67,"city":35,"state":68,"zip":13,"country":37,"countryCode":13,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"Asan Medical Center","NOT_YET_RECRUITING","Songpa-gu",{"type":39,"coordinates":70},[41,42],{"lat":42,"lon":41},[73,77],{"name":74,"role":25,"phone":75,"phoneExt":47,"email":76},"Dae-ho Lee, MD","2-3010-5925","leedaeho@amc.seoul.kr",{"name":78,"role":25,"phone":75,"phoneExt":79,"email":80},"Da-yi Joung","2","joungdayi@naver.com",{"type":82,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"SPONSOR_INVESTIGATOR","Se-Hoon Lee","Professor","100330126",false,"NCT03578185","Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy","LC_Biomarker","Inclusion Criteria:\n\n1. aged above or equal to 18\n2. Histologically confirmed lung cancer patients\n3. Patient treated with immune checkpoint inhibitor\n\nExculsion Criteria:\n\nNA","ALL","18 Years",{"count":94,"type":95},800,"ESTIMATED","OBSERVATIONAL","This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.",[99],"Lung Cancer","2024-11-29",{"date":102,"type":103},"2024-12-03","ACTUAL",{"date":105,"type":103},"2018-04-11",{"date":107,"type":95},"2025-12-31",{"name":83,"class":6},3]